You can seek FDA approval to launch a generic drug before the expiration of CIPRODEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CIPRODEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CIPRODEX:-

You can seek FDA approval to launch a generic drug before the expiration of COMBIVENT RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMBIVENT RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMBIVENT RESPIMAT:-

You can seek FDA approval to launch a generic drug before the expiration of DIPRIVAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DIPRIVAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DIPRIVAN:-

You can seek FDA approval to launch a generic drug before the expiration of EDARBI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EDARBI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EDARBI:-

You can seek FDA approval to launch a generic drug before the expiration of EDARBYCLOR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EDARBYCLOR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EDARBYCLOR:-

You can seek FDA approval to launch a generic drug before the expiration of FOLOTYN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FOLOTYN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FOLOTYN:-

You can seek FDA approval to launch a generic drug before the expiration of FYCOMPA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FYCOMPA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FYCOMPA:-

You can seek FDA approval to launch a generic drug before the expiration of KUVAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KUVAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KUVAN:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of MIRVASO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MIRVASO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MIRVASO:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of SPIRIVA RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SPIRIVA RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SPIRIVA RESPIMAT:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of XIFAXAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XIFAXAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XIFAXAN:-

You can seek FDA approval to launch a generic drug before the expiration of XTAMPZA ER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XTAMPZA ER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XTAMPZA ER:-

You can seek FDA approval to launch a generic drug before the expiration of ZOMETA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZOMETA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZOMETA:-